Navigation Links
United Therapeutics Corporation Reports Second Quarter 2013 Financial Results
Date:7/25/2013

trative expense

$

71,365$

53,25834.0

%General and administrative. The increase in general and administrative expense of $4.2 million for the quarter ended June 30, 2013 compared to the same quarter in 2012 was driven by increases in (1) salaries and operating expenses associated with the expansion of our business, (2) professional fees and (3) grants to non-affiliated, non-profit organizations that provide financial assistance to patients with pulmonary arterial hypertension. These increases were offset in part by a $6.8 million impairment charge on an acquired contract-based intangible we recognized during three months ended June 30, 2012.

Share-based compensation. The increase in share-based compensation of $13.7 million for the quarter ended June 30, 2013, compared to the same quarter in 2012, resulted from the appreciation in the price of our common stock.

Income TaxesThe provision for income taxes was $38.7 million for the quarter ended June 30, 2013, compared to $31.0 million for the same quarter in 2012. The estimated annual effective tax rate was 33 percent and 32 percent as of June 30, 2013 and 2012, respectively.

2013 Revenue GuidanceWe reaffirm our 2013 full-year revenue guidance for our three commercial products (Remodulin®, Tyvaso® and Adcirca®), as we continue to expect related revenues to fall within a range of 5% above or below $1.0 billion for 2013.

Earnings Before Non-Cash ChargesEarnings before non-cash charges is defined as net income, adjusted for the following non-cash charges, as applicable: (1) interest; (2) income taxes; (3) license fees; (4) depreciation and amortization; (5) impairment charges; and (6) share-based compensation (stock option, share tracking award and employee stock purchase plan expense).

A reconciliation of net income to earnings before non-cash charge
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. United Therapeutics Corporation to Announce Second Quarter 2013 Financial Results Before Market Open on Thursday, July 25, 2013
2. Before the Bell Scans: Pharmacyclics, United Therapeutics, Impax Laboratories, and Star Scientific
3. Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol"
4. Centre for Sight First in the United Kingdom to Utilize TrueVision® 3D Visualization During Femtosecond Laser Cataract Surgery
5. Prevagen® is the Number One Branded Memory Supplement in the United States
6. SPIE on Global Team Proposing ‘international Year of Light’ at United Nations
7. United Airlines and AltAir Fuels to Bring Commercial-Scale, Cost-Competitive Biofuels to Aviation Industry
8. Despite Lucentiss Recent Expanded Label for Diabetic Macular Edema, Avastin Remains the Preferred Intravitreal Therapy for Diabetic Macular Edema in the United States
9. Atlantic Peptides Teams Up with a United Kingdom Company to Offer cGMP Peptides and API
10. SoundConnect Announces Lync Release in the United States
11. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... DC (PRWEB) January 14, 2014 Carahsoft ... for Thursday, January 23, 2014 at 2pm EST (11am ... Knowledge.” The topic focuses on how technology can turn ... critical decisions for government agencies. The online webinar will ...
(Date:1/14/2014)... pet owners drew up their lists of New Year,s resolutions for ... of my furry companion." Nowadays there are pet salons, dog and ... take the little canine or feline darlings along wherever mommy or ... pricey toys at the pet store. But anyone who has ever ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
(Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... subsidiary in Philadelphia Area -, PHILADELPHIA, Feb. ... cellular imaging, announced today the appointment of Chris ... subsidiary of Paris-based Mauna,Kea Technologies and develops and ... improves patient care by eliminating the,need for unnecessary ...
... Prescription Rates, According ... to a New Report from Decision Resources, WALTHAM, ... leading research and advisory firms focusing on pharmaceutical and,healthcare ... ustekinumab will become the clinical gold standard,for psoriasis by ...
... the world,s leading,online bioscience job board and life ... pharmaceutical job candidates at its Biotech,Bay Career Fair ... The BioSpace Career Fair drew a steady ... career candidates from,around the Northern California region. For ...
Cached Biology Technology:Chris Tihansky Appointed President of In Vivo Cellular Imaging Leader Cellvizio Inc. 2Centocor/Janssen-Cilag's Ustekinumab Will Become the Gold Standard for Psoriasis By 2011 2BioSpace Career Fair in San Francisco Welcomes Over 1,000 Bioscience Professionals 2
(Date:4/22/2014)... London PETA International Science Consortium Ltd.,s nanotechnology expert ... strategy for nanomaterial hazard assessment" at the 7th ... 2014, in Antalya, Turkey. , Dr. Monita Sharma ... from the US National Academy of Sciences, " Toxicity ... Strategy ," which recommends use of non-animal methods involving ...
(Date:4/22/2014)... nanotechnology researchers at the University of Kentucky has discovered ... using RNA. , The research, led by Peixuan ... Nanobiotechnology at the UK College of Pharmacy and Markey ... as a Boiling-Resistant Anionic Polymer Material To Build Robust ... F. Khisamutdinov and Daniel L. Jasinski. , The article, ...
(Date:4/22/2014)... and precipitation on the global distribution of plant and ... the UV-B radiation, is often neglected. The landscape ecologists ... Universities in Olomouc (Czechia), Halle and Lneburg have processed ... such a way that they can be used to ... The basic input data were provided by a NASA ...
Breaking Biology News(10 mins):RNA shows potential as boiling-resistant anionic polymer material for nanoarchitectures 2UV-radiation data to help ecological research 2
... in Uganda who self-paid for their antiretroviral medications experienced ... or supply logistical disruptions. These treatment interruptions led ... patients. , These findings by a team led by ... Kampala, and UCSF are reported in the April 22, ...
... pediatric specialists at Baylor College of Medicine have discovered a ... that allows drugs to enter cancer cells. , The research ... and Biomolecular Chemistry. , All living cells defend themselves ... form a protective cocoon around the cell's inner machinery and ...
... cells to turnover their contents, something that they do ... and radiation, but it is not known if this ... survive the anti-cancer therapy. However, in a study using ... the University of Pennsylvania have now shown that autophagy ...
Cached Biology News:Resistance to anti-HIV drugs in Uganda developed due to drug supply problems 2Buckyballs used as 'passkey' into cancer cells 2
Recombinant Viral CCI/Fc Chimera, CF...
... DeStreak Reagent, 1 ml. ... 2-D gels by preventing streaking.Eliminates ... oxidation of proteins.Stabilizes proteins throughout ... simplified, well-resolved protein patterns.Ideal for ...
LIVE/DEAD® Cell-Mediated Cytotoxicity Kit *for animal cells* *2000 assays*...
SlowFade Antifade Kit with DAPI...
Biology Products: